RecallDepth
Class III Terminated

Susvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vial and One Susvimo initial fill needle, NDC 50242-078-55; and b) carton labeled as Susvimo Ocular Implant with Insertion Tool Assembly, containing One carrier with implant and One insertion Tool, UDI 81004259001, GTIN 00810042590014, Rx only, Genentech, Inc., A Member of the Roche Group, South San Francisco, CA 94080-4990.

Company
Genentech, Inc.
Recall Initiated
October 18, 2022
Posted
November 9, 2022
Recall Number
D-0025-2023
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
452 vials and implants
Firm Location
South San Francisco, CA, United States

Reason for Recall

Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.

Distribution

Nationwide in the USA

Lot / Code Info

Lot/Exp: a) 3499188, Exp 10/31/2022; Lot 3523071, Exp 6/30/2023; b) 3456735, Exp 10/23/2026; 3456737; Exp 10/29/2026; 3477671, Exp 10/31/2026; 3480781, Exp 12/19/2026; 3506526, Exp 02/25/2027; 3506531, Exp 04/15/2027

More recalls by Genentech, Inc.

View all recalls by this company →

Other recent Class III Drug recalls